a public good project by the
Synthesis
Company
of California

© 2026

Milton L. Hammond | doi.page

0 works0 citations0 h-index

Milton L. Hammond

Merck & Co., Inc., Rahway, NJ, USA (United States)(US)

Publications by Year

Research Areas

Estrogen and related hormone effects, Bioactive Compounds and Antitumor Agents, Antibiotic Resistance in Bacteria, Antibiotics Pharmacokinetics and Efficacy, Crystallization and Solubility Studies

Most-Cited Works

→ Succinic Acids as Potent Inhibitors of Plasmid-borne IMP-1 Metallo-β-lactamase(2001)200 cited
→ Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®(2014)159 cited
→ Cytochrome P450 3A4-Mediated Bioactivation of Raloxifene: Irreversible Enzyme Inhibition and Thiol Adduct Formation(2002)156 cited
→ 6H-Benzo[c]chromen-6-one derivatives as selective ERβ agonists(2006)144 cited
→ In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa(2019)121 cited
→ Selective transamination and optical induction by a .beta.-cyclodextrin-pyridoxamine artificial enzyme(1980)117 cited
→ Synthesis and Antifungal Activity of Novel Cationic Pneumocandin Bo Derivatives

(1994)

112 cited

→ Estrogen Receptor Ligands. II. Discovery of Benzoxathiins as Potent, Selective Estrogen Receptor α Modulators(2004)99 cited

→ In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin(1992)93 cited

→ Discovery of Novel Tricyclic Full Agonists for the G-Protein-Coupled Niacin Receptor 109A with Minimized Flushing in Rats(2009)78 cited